Abstract
Background Studies have reported that female sex predicts superior cardiac resynchronization therapy (CRT) response. One theory is that this association is related to smaller female heart size, thus increased “relative dyssynchrony” at given QRS durations (QRSd).
Objective To investigate the mechanisms of sex-specific CRT response relating to heart size, relative dyssynchrony, cardiomyopathy type, QRS morphology, and other patient characteristics.
Methods A post-hoc analysis of the MORE-CRT MPP trial (n=3739, 28% female), with a sub-group analysis of patients with non-ischaemic cardiomyopathy (NICM) and left bundle branch block (LBBB) (n=1308, 41% female) to control for confounding characteristics. A multivariable analysis examined predictors of response to 6 months of conventional CRT, including sex and relative dyssynchrony, measured by QRSd/LVEDV (left ventricular end-diastolic volume).
Results Females had a higher CRT response rate than males (70.1% vs. 56.8%, p<0.0001). Subgroup analysis: Regression analysis of the NICM LBBB subgroup identified QRSd/LVEDV, but not sex, as a modifier of CRT response (p<0.0039). QRSd/LVEDV was significantly higher in females (0.919) versus males (0.708, p<0.001). CRT response was 78% for female patients with QRSd/LVEDV>median value, compared to 68% < median value (p=0.012). Association between CRT response and QRSd/LVEDV was strongest at QRSd<150ms.
Conclusions In the NICM LBBB population, increased relative dyssynchrony in females, who have smaller heart sizes than their male counterparts, is a driver of sex-specific CRT response, particularly at QRSd <150ms. Females may benefit from CRT at a QRSd <130ms, opening the debate on whether sex-specific QRSd cut-offs or QRS/LVEDV measurement should be incorporated into clinical guidelines.
Competing Interest Statement
Kwangdeok Lee, Wenjiao Lin and Andrea Grammatico are employed by Abbott
Clinical Trial
NCT02006069
Funding Statement
The NW, VM, FdV, and SH are supported by the Wellcome/EPSRC Centre for Medical Engineering (WT203148/Z/16/Z). NW receives fellowship funding from the British Heart Foundation (FS/CRTF/22/24362). SAN acknowledges support from the UK Engineering and Physical Sciences Research Council (EP/M012492/1, NS/A000049/1, and EP/P01268X/1), the British Heart Foundation (PG/15/91/31812,PG/13/37/30280, SP/18/6/33805), US National Institutes of Health (NIH R01-HL152256), European Research Council (ERC PREDICT-HF 864055) and Kings Health Partners London National Institute for Health Research (NIHR) Biomedical Research Centre. BT receives research support from Abbott. MG received lecture and/or consultation fees from Abbott, Medtronic, Boston Scientific, Biotronik and MicroPort. CL receives speaker fees from Medtronic, Abbott and Biotronik. CAR receives research funding and/or consultation fees from Abbott, Medtronic, Boston Scientific, Spectranetics, EBR Systems and MicroPort outside of the submitted work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is a post-hoc analysis of the MORE-CRT MPP trial sponsored by Abbott
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflict of Interests / Funding Statement: The NW, VM, FdV, and SH are supported by the Wellcome/EPSRC Centre for Medical Engineering (WT203148/Z/16/Z). NW receives fellowship funding from the British Heart Foundation (FS/CRTF/22/24362). SAN acknowledges support from the UK Engineering and Physical Sciences Research Council (EP/M012492/1, NS/A000049/1, and EP/P01268X/1), the British Heart Foundation (PG/15/91/31812,PG/13/37/30280, SP/18/6/33805), US National Institutes of Health (NIH R01-HL152256), European Research Council (ERC PREDICT-HF 864055) and Kings Health Partners London National Institute for Health Research (NIHR) Biomedical Research Centre. BT receives research support from Abbott. MG received lecture and/or consultation fees from Abbott, Medtronic, Boston Scientific, Biotronik and MicroPort. CL receives speaker fees from Medtronic, Abbott and Biotronik. CAR receives research funding and/or consultation fees from Abbott, Medtronic, Boston Scientific, Spectranetics, EBR Systems and MicroPort outside of the submitted work.
Data Availability
Data can be requested from the study sponsor.